Works matching IS 01676997 AND DT 2024 AND VI 42 AND IP 2

Results: 8

A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 2, p. 221, doi. 10.1007/s10637-024-01430-6

By:

Ko, Andrew H.;
Coveler, Andrew L.;
Schlechter, Benjamin L.;
Bekaii-Saab, Tanios;
Wolpin, Brian M.;
Clark, Jeffrey W.;
Bockorny, Bruno;
Bai, Li-Yuan;
Lin, Yu-Chin;
Chiang, Evelyn;
Langecker, Peter;
Lin, Shih-Yao

Publication type:

Article

The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages.

Published in:

Investigational New Drugs, 2024, v. 42, n. 2, p. 207, doi. 10.1007/s10637-024-01427-1

By:

Henning, Petra;
Westerlund, Anna;
Movérare-Skrtic, Sofia;
Lindholm, Catharina;
Márquez-Méndez, Marcela;
Nilsson, Sten;
Holmberg, Anders R.;
Lerner, Ulf H.

Publication type:

Article

Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2024, v. 42, n. 2, p. 185, doi. 10.1007/s10637-024-01426-2

By:

Li, Xinxiu;
Su, Hongmeng;
Tang, Wenqing;
Shu, Shihui;
Zhao, Luyu;
Sun, Jinghan;
Fan, Hong

Publication type:

Article

PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.

Published in:

Investigational New Drugs, 2024, v. 42, n. 2, p. 171, doi. 10.1007/s10637-024-01425-3

By:

Gou, Miaomiao;
Zhang, Yong;
Wang, Zhikuan;
Qian, Niansong;
Dai, Guanghai

Publication type:

Article

First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?

Published in:

Investigational New Drugs, 2024, v. 42, n. 2, p. 196, doi. 10.1007/s10637-024-01424-4

By:

Zhao, Yuanyuan;
Mei, Ting;
Na, Feifei;
Tian, Xiaoman;
Ao, Rui;
Long, Xiangyu;
Luo, Qiang;
Duan, Ping;
Zhu, Jiang;
Wang, Yongsheng;
Huang, Meijuan;
Liu, Yongmei;
Gong, Youling

Publication type:

Article

Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 2, p. 161, doi. 10.1007/s10637-024-01423-5

By:

Chang, Lele;
Zhang, Xuemei;
Ma, Qian;
Kong, Lingyang;
Yu, Yang;
Tao, Ji;
Li, Qingwei

Publication type:

Article

A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.

Published in:

Investigational New Drugs, 2024, v. 42, n. 2, p. 179, doi. 10.1007/s10637-024-01419-1

By:

Beckermann, Kathryn E.;
Patnaik, Amita;
Winer, Ira;
Tan, Winston;
Bashir, Babar;
Kyriakopoulos, Christos E.;
Sweis, Randy F.;
Chamberlain, Marc;
Rini, Brian I.

Publication type:

Article

Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status.

Published in:

Investigational New Drugs, 2024, v. 42, n. 2, p. 229, doi. 10.1007/s10637-024-01418-2

By:

Shaykevich, Aaron;
Chae, Danbee;
Silverman, Isaac;
Bassali, Jeremy;
Louloueian, Netanel;
Siegman, Alexander;
Bandyopadhyaya, Gargi;
Goel, Sanjay;
Maitra, Radhashree

Publication type:

Article